Human Thioredoxin (TXN): A Comprehensive Functional Annotation Report

1. Introduction and Summary

Human thioredoxin (TXN, also known as TRX, TRX1, or TRDX) is a small (approximately 12 kDa), ubiquitous redox protein that plays central roles in cellular redox homeostasis, antioxidant defense, and signal transduction. Originally identified in Escherichia coli by Laurent et al. in 1964 as a hydrogen donor for ribonucleotide reductase, the human homolog was subsequently characterized and found to have expanded functions beyond its bacterial counterpart [holmgren-1985-thioredoxin-abstract]. Remarkably, human TXN was independently discovered as the "adult T cell leukemia-derived factor" (ADF), a secreted protein from HTLV-I-transformed T-cells with cytokine-like and chemokine-like activities, highlighting its multifunctional nature [leveillard-2017-extracellular-trx-abstract].

The primary biochemical function of thioredoxin is as a protein disulfide oxidoreductase (thiol-disulfide reductase), catalyzing the reduction of disulfide bonds in target proteins using electrons ultimately derived from NADPH via the thioredoxin reductase (TXNRD) system [lu-holmgren-2013-thioredoxin-antioxidant-abstract]. This enzymatic activity is mediated by the conserved Cys-Gly-Pro-Cys (CGPC) active site motif, which constitutes the hallmark of the thioredoxin family. The protein operates as part of the thioredoxin system—comprising NADPH, thioredoxin reductase (TXNRD1), and thioredoxin itself—which together with the glutathione-glutaredoxin system controls the cellular redox environment in mammalian cells [lu-holmgren-2013-thioredoxin-antioxidant-abstract].

2. Catalytic Mechanism and Substrate Specificity

2.1 The Thioredoxin Fold and Active Site

The three-dimensional structure of thioredoxin, solved by both X-ray crystallography and NMR spectroscopy, reveals the canonical "thioredoxin fold" consisting of a central four-stranded β-sheet flanked by three α-helices [holmgren-1995-trx-structure-mechanism-abstract]. The redox-active site is located on a loop connecting a β-strand to an α-helix, positioning the two catalytic cysteine residues (Cys32 and Cys35 in human TXN) for optimal redox activity. This structural motif has been conserved across all domains of life and serves as the foundation for the thioredoxin superfamily, which includes protein disulfide isomerases, glutaredoxins, and numerous other thiol-disulfide oxidoreductases [fujimoto-2018-substrates-abstract].

2.2 Catalytic Mechanism

The catalytic mechanism of thioredoxin involves a two-step thiol-disulfide exchange reaction. In the first step, the more N-terminal cysteine (Cys32), which exists as a thiolate anion at physiological pH due to its unusually low pKa (~7.1), performs a nucleophilic attack on the disulfide bond of the target protein, forming a transient mixed disulfide intermediate. In the second step, the C-terminal cysteine (Cys35) attacks this mixed disulfide, releasing the reduced target protein and generating oxidized thioredoxin containing an intramolecular disulfide bond [holmgren-1995-trx-structure-mechanism-abstract].

High-resolution solution structures of human and E. coli thioredoxin in both oxidized and reduced states support this catalytic model, demonstrating conformational changes upon oxidation that are crucial for function [holmgren-1995-trx-structure-mechanism-abstract]. The oxidized thioredoxin is then regenerated to its reduced form by thioredoxin reductase (TXNRD1 in the cytosol) using electrons from NADPH [mustacich-powis-2000-txnrd-abstract].

2.3 Substrate Specificity

Thioredoxin exhibits broad substrate specificity, reducing disulfide bonds in numerous protein substrates. Key substrates include:

1. Ribonucleotide reductase (RNR): Thioredoxin serves as the primary electron donor for RNR, the enzyme that catalyzes the rate-limiting step in DNA synthesis by converting ribonucleotides to deoxyribonucleotides. After each catalytic cycle, a disulfide bond forms at the RNR active site, which must be reduced by thioredoxin for continued activity [lu-holmgren-2013-thioredoxin-antioxidant-abstract].

2. Peroxiredoxins (Prxs): These thiol-dependent peroxidases use thioredoxin as their primary electron donor to reduce hydrogen peroxide, organic hydroperoxides, and peroxynitrite. The thioredoxin-peroxiredoxin system constitutes a major cellular defense against oxidative stress, with reaction rates that are extremely fast [lu-holmgren-2013-thioredoxin-antioxidant-abstract].

3. Methionine sulfoxide reductases (Msrs): Thioredoxin provides reducing equivalents to MsrA and MsrB, enzymes that repair oxidized methionine residues in proteins, thereby contributing to protein repair mechanisms [lu-holmgren-2013-thioredoxin-antioxidant-abstract].

4. Transcription factors: Multiple redox-sensitive transcription factors including NF-κB, AP-1, p53, HIF-1α, and others contain critical cysteine residues in their DNA-binding domains that must be reduced for DNA binding activity. Thioredoxin directly or indirectly reduces these cysteines to regulate transcription factor activity [sen-packer-1996-redox-regulation-abstract].

3. Subcellular Localization

3.1 Cytoplasmic and Nuclear Distribution

Human thioredoxin-1 (TXN) is predominantly a cytoplasmic protein under basal conditions, but it translocates to the nucleus in response to various stimuli including oxidative stress, cell density changes, and growth factor stimulation [spielberger-2008-trx-localization-abstract]. Studies have demonstrated that the subcellular distribution of thioredoxin is dynamic and influenced by the cellular redox environment. In sparse cell cultures with higher reactive oxygen species (ROS) levels, thioredoxin-1 is predominantly nuclear, whereas in confluent cultures it is predominantly cytoplasmic [spielberger-2008-trx-localization-abstract].

The nuclear localization of thioredoxin is functionally significant, as it enables the reduction of redox-sensitive transcription factors. Research has shown that the redox state of key transcription factors like NF-κB differs between the cytoplasm and nucleus: the critical cysteine residue (Cys-62 of p50) is highly oxidized in the cytoplasm and must be converted to a reduced form in the nucleus to enable DNA binding [ando-2008-ape1-ref1-abstract]. Thioredoxin, together with APE1/Ref-1, mediates this nuclear reduction and activation.

3.2 Mitochondrial Thioredoxin

Mammalian cells possess a separate mitochondrial thioredoxin system, consisting of thioredoxin-2 (TXN2) and mitochondrial thioredoxin reductase (TXNRD2). This compartmentalized system is critical for mitochondrial redox homeostasis and protection against oxidative stress. Thioredoxin-2 has been identified as a critical regulator of cytochrome c release and mitochondrial apoptosis [masutani-2005-trx-apoptosis-abstract].

3.3 Extracellular Secretion

A striking feature of human thioredoxin is its secretion from cells despite lacking a classical N-terminal signal peptide. Human TXN was originally discovered as a secreted protein (ADF) from HTLV-I-transformed T-cells [leveillard-2017-extracellular-trx-abstract]. Thioredoxin secretion is induced by various stimuli including oxidative stress and cytokine stimulation. The secretion mechanism remains incompletely understood but is classified as unconventional protein secretion [leveillard-2017-extracellular-trx-abstract].

Extracellular thioredoxin exhibits cytokine-like and chemokine-like activities. A complete extracellular thioredoxin system exists in blood, with circulating TXN1 and TXNRD1 detected in plasma. However, the source of extracellular NADPH required for thioredoxin recycling remains mysterious. In the absence of regenerative capacity, extracellular thioredoxins may paradoxically act as pro-oxidant rather than antioxidant agents [leveillard-2017-extracellular-trx-abstract].

TRX80, an 80-amino acid N-terminal truncated form of thioredoxin-1, is generated by cleavage via ADAM10 and ADAM17 metalloproteinases in monocytes. TRX80 has distinct biological activities from full-length thioredoxin, acting as a cytokine for monocytes, promoting proinflammatory macrophage phenotype, and activating complement pathways [leveillard-2017-extracellular-trx-abstract].

4. Signaling Pathways and Transcription Factor Regulation

4.1 The Thioredoxin-APE1/Ref-1 Redox Signaling Pathway

One of the most important functions of thioredoxin is the regulation of redox-sensitive transcription factors. At least two major transcription factors, NF-κB and AP-1, have been identified as regulated by the intracellular redox state, with thioredoxin playing a central role [sen-packer-1996-redox-regulation-abstract].

The multifunctional protein APE1/Ref-1 (apurinic/apyrimidinic endonuclease 1/redox factor 1) cooperates with thioredoxin in this regulatory pathway. APE1/Ref-1 not only directly reduces target transcription factors but also facilitates their reduction by other reducing molecules including glutathione and thioredoxin—a function termed "redox chaperone activity" [ando-2008-ape1-ref1-abstract]. This redox chaperone activity operates at significantly lower concentrations than required for direct redox activity and is independent of APE1/Ref-1's own cysteine residues, suggesting a conformational facilitation mechanism.

4.2 NF-κB Regulation

NF-κB is a critical transcription factor regulating immune responses, inflammation, and cell survival. The redox-sensitive cysteine residue Cys-62 in the p50 subunit of NF-κB must be reduced for efficient DNA binding. Thioredoxin, working with APE1/Ref-1, reduces this cysteine in the nucleus to enable transcriptional activation [ando-2008-ape1-ref1-abstract][hirota-2000-nucleoredoxin-abstract].

Interestingly, thioredoxin, glutaredoxin, and nucleoredoxin differentially regulate NF-κB, AP-1, and CREB activation in cells. These redox molecules have distinct subcellular localizations and differentially modulate transcription factor activation induced by TNFα, PMA, and other stimuli [hirota-2000-nucleoredoxin-abstract].

4.3 AP-1 Regulation

The transcription factor AP-1 (composed of c-Fos and c-Jun heterodimers) is regulated by thioredoxin through reduction of conserved cysteine residues in the basic leucine zipper (bZIP) DNA-binding domains (Cys-272 of c-Fos and Cys-154 of c-Jun). APE1/Ref-1 promotes the reduction of both c-Fos and c-Jun bZIP domains by thioredoxin or glutathione, facilitating AP-1 DNA binding activity [ando-2008-ape1-ref1-abstract].

4.4 Other Transcription Factors

Thioredoxin also regulates the activity of numerous other transcription factors including:
- p53: The tumor suppressor p53 requires reduced cysteine residues for DNA binding; thioredoxin maintains p53 in its active reduced state
- HIF-1α: Hypoxia-inducible factor 1α, critical for oxygen sensing and angiogenesis
- Pax proteins: Paired box transcription factors important in development
- Egr-1: Early growth response factor involved in cell proliferation
- STAT3: Signal transducer and activator of transcription 3

[thakur-2014-ape1-ref1-abstract]

4.5 ASK1-Thioredoxin Interaction and Apoptosis Signaling

A critical signaling pathway involving thioredoxin is its interaction with apoptosis signal-regulating kinase 1 (ASK1), a MAP kinase kinase kinase that lies upstream of JNK and p38 MAPK pathways leading to apoptosis. Reduced thioredoxin binds directly to ASK1 and inhibits its kinase activity. Upon oxidative stress, thioredoxin becomes oxidized and dissociates from ASK1, allowing ASK1 activation and downstream apoptotic signaling [masutani-2005-trx-apoptosis-abstract].

Research has demonstrated that cell exposure to H₂O₂ causes rapid oxidation of ASK1, leading to its multimerization through interchain disulfide bonds. During the subsequent reduction phase, thioredoxin-1 becomes covalently associated with ASK1 to restore its reduced monomeric state. Overexpression of thioredoxin accelerates ASK1 reduction and impairs JNK activation and apoptosis [nadeau-2007-ask1-trx-abstract]. This establishes thioredoxin as a sensor of oxidative stress that modulates the apoptotic threshold.

4.6 TXNIP Interaction

Thioredoxin-interacting protein (TXNIP, also known as TBP-2 or vitamin D₃ upregulated protein 1/VDUP1) is a negative regulator of thioredoxin. TXNIP binds to reduced thioredoxin and inhibits its reducing activity. The TXNIP-thioredoxin interaction has been implicated in metabolic regulation, including glucose and lipid metabolism, and in tumor suppression [lillig-holmgren-2007-trx-related-molecules-abstract].

5. The Thioredoxin System as an Antioxidant Defense

5.1 The Complete Thioredoxin System

The mammalian thioredoxin system consists of three components: NADPH (the ultimate electron donor), thioredoxin reductase (TXNRD), and thioredoxin itself. NADPH is generated primarily through the pentose phosphate pathway, linking thioredoxin function to glucose metabolism [leveillard-2017-extracellular-trx-abstract].

Mammalian thioredoxin reductases (TXNRD1, TXNRD2, and TXNRD3) are distinct from bacterial enzymes in that they are high molecular weight selenoenzymes containing an essential selenocysteine residue at the C-terminus [mustacich-powis-2000-txnrd-abstract]. The selenocysteine-containing C-terminal motif (-Cys-SeCys-) provides mammalian thioredoxin reductases with broader substrate specificity compared to their bacterial counterparts.

5.2 Crosstalk with Glutathione System

The thioredoxin and glutathione systems were traditionally viewed as parallel but independent antioxidant pathways. However, recent research has revealed significant crosstalk between these systems, with each capable of serving as a backup for the other under conditions of impairment [lu-holmgren-2013-thioredoxin-antioxidant-abstract]. Glutaredoxins can accept electrons from glutathione and reduce some overlapping substrates with thioredoxin.

5.3 Peroxiredoxin Reduction

A major antioxidant function of thioredoxin is providing electrons to peroxiredoxins (Prxs), a family of thiol-dependent peroxidases that catalyze the reduction of H₂O₂, organic hydroperoxides, and peroxynitrite. The thioredoxin-peroxiredoxin system represents a highly efficient mechanism for hydrogen peroxide removal, with extremely fast reaction rates [lu-holmgren-2013-thioredoxin-antioxidant-abstract].

6. Structure-Function Relationships

6.1 The Thioredoxin Fold

The thioredoxin fold represents one of the most ancient and conserved protein structural motifs, found across all domains of life. The core structure consists of a central four-stranded β-sheet flanked by α-helices, with the redox-active CXXC motif positioned at the N-terminus of an α-helix [fujimoto-2018-substrates-abstract].

The thioredoxin superfamily encompasses numerous proteins sharing this fold, including:
- Thioredoxins (cytosolic, mitochondrial)
- Glutaredoxins
- Protein disulfide isomerases
- Glutathione peroxidases (some family members)
- Peroxiredoxins

6.2 Active Site Properties and the CXXC Rheostat

The catalytic cysteines in human thioredoxin (Cys32-Gly-Pro-Cys35) exhibit distinct chemical properties. The N-terminal Cys32 has a low pKa (~7.1) due to its local environment, existing predominantly as the reactive thiolate anion at physiological pH. This nucleophilic thiolate initiates the catalytic cycle by attacking substrate disulfides. The proline residue creates a characteristic kink in the active site loop, and glycine provides conformational flexibility [holmgren-1995-trx-structure-mechanism-abstract].

The CXXC motif functions as a biochemical "rheostat" that determines the reduction potential of thiol-disulfide oxidoreductases [chivers-1997-cxxc-motif-abstract]. The identity of the XX dipeptide between the two catalytic cysteines profoundly affects the redox properties: the pKa of the N-terminal cysteine correlates with the reduction potential, such that lower pKa values make the disulfide bond easier to reduce. However, formal analysis of the Nernst equation reveals that reduction potential contains both pH-dependent and pH-independent components. The differences in reduction potential between thioredoxin (CGPC, approximately -270 mV) and other thiol-disulfide oxidoreductases like DsbA (CPHC, approximately -120 mV) cannot be explained solely by thiol pKa values, indicating that additional structural factors contribute to tuning the redox potential [chivers-1997-cxxc-motif-abstract]. These intricacies enable the thioredoxin superfamily to span a wide range of reduction potentials and thereby serve diverse biochemical roles.

7. Genetic Evidence for Essential Functions

The essential nature of thioredoxin has been demonstrated through genetic studies in model organisms. Global deletion of thioredoxin-1 in mice results in embryonic lethality, underscoring its essential role in development. To circumvent this lethality, tissue-specific knockout models have been generated that provide critical insights into thioredoxin function in specific organs.

Cardiac-specific thioredoxin-1 knockout (Trx1cKO) mice were viable at birth but died with a median survival age of only 25.5 days [oka-2020-trx1-knockout-heart-abstract]. These mice developed severe heart failure characterized by contractile dysfunction, hypertrophy, increased fibrosis, and apoptotic cell death. RNA-sequencing revealed marked downregulation of genes involved in energy production, and mitochondrial morphological abnormalities were evident. Even heterozygous cardiac Trx1 knockout mice, while viable at baseline, showed exacerbated cardiac dysfunction under pressure-overload stress, demonstrating haploinsufficiency under stress conditions.

Mechanistically, this study revealed that thioredoxin-1 regulates the mechanistic target of rapamycin (mTOR) through reduction of Cys1483. In Trx1cKO hearts, mTOR was more oxidized, and phosphorylation of mTOR substrates (S6K and 4EBP1) was impaired. An oxidation-resistant mTOR mutant (C1483F) prevented the metabolic gene suppression caused by thioredoxin knockdown, directly demonstrating that thioredoxin maintains mTOR function through redox regulation [oka-2020-trx1-knockout-heart-abstract]. These findings establish that endogenous thioredoxin is essential for maintaining cardiac function and metabolism through mTOR-mediated regulation of mitochondrial gene expression.

8. Implications for Disease and Therapeutic Applications

Thioredoxin has been implicated in numerous disease contexts:

1. Cancer: Thioredoxin and thioredoxin reductase are often overexpressed in tumors, contributing to tumor cell survival under oxidative stress and resistance to chemotherapy. Thioredoxin inhibition represents a potential therapeutic strategy [lu-holmgren-2013-thioredoxin-antioxidant-abstract].

2. Infectious Diseases: The distinct structural features of mammalian versus bacterial thioredoxin reductases offer opportunities for selective targeting of pathogenic bacteria [lu-holmgren-2013-thioredoxin-antioxidant-abstract].

3. Cardiovascular Disease: Extracellular thioredoxin levels serve as biomarkers for oxidative stress and inflammation in various conditions including acute lung injury [lu-holmgren-2013-thioredoxin-antioxidant-abstract].

4. Neurodegeneration: The thioredoxin system plays protective roles against oxidative damage in neurons.

9. Open Questions

Despite extensive research on thioredoxin over several decades, several important questions remain:

1. Secretion Mechanism: The unconventional secretion pathway for thioredoxin remains poorly understood. How does this cytosolic protein without a signal peptide reach the extracellular space?

2. Extracellular NADPH: The source of extracellular NADPH required for regeneration of secreted thioredoxin remains mysterious. In its absence, what determines whether extracellular thioredoxin acts as a reductant or oxidant?

3. Substrate Selectivity Determinants: What structural features beyond the CXXC motif and thioredoxin fold determine the specificity of thioredoxin for particular protein substrates?

4. Nuclear Import Mechanism: The mechanism by which thioredoxin translocates to the nucleus in response to oxidative stress requires further characterization.

5. TRX80 Signaling: The receptors and signaling pathways mediating the cytokine-like activities of TRX80 remain incompletely characterized.

6. Tissue-Specific Functions: How does thioredoxin function differ across different tissues and cell types, and what accounts for these differences?

7. Therapeutic Window: Can thioredoxin or thioredoxin reductase be selectively targeted in disease states without disrupting essential cellular functions?

10. References

• holmgren-1985-thioredoxin-abstract: Holmgren A. Thioredoxin. Annu Rev Biochem. 1985;54:237-71. PMID: 3896121. DOI: 10.1146/annurev.bi.54.070185.001321

• lu-holmgren-2013-thioredoxin-antioxidant-abstract: Lu J, Holmgren A. The thioredoxin antioxidant system. Free Radic Biol Med. 2013;66:75-87. PMID: 23899494. DOI: 10.1016/j.freeradbiomed.2013.07.036

• holmgren-1995-trx-structure-mechanism-abstract: Holmgren A. Thioredoxin structure and mechanism: conformational changes on oxidation of the active-site sulfhydryls to a disulfide. Structure. 1995;3(3):239-43. PMID: 7788289. DOI: 10.1016/s0969-2126(01)00153-8

• mustacich-powis-2000-txnrd-abstract: Mustacich D, Powis G. Thioredoxin reductase. Biochem J. 2000;346 Pt 1:1-8. PMID: 10657232. PMC: PMC1220815.

• sen-packer-1996-redox-regulation-abstract: Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J. 1996;10(7):709-20. PMID: 8635688. DOI: 10.1096/fasebj.10.7.8635688

• hirota-2000-nucleoredoxin-abstract: Hirota K, et al. Nucleoredoxin, glutaredoxin, and thioredoxin differentially regulate NF-kappaB, AP-1, and CREB activation in HEK293 cells. Biochem Biophys Res Commun. 2000;274(1):177-82. PMID: 10903915. DOI: 10.1006/bbrc.2000.3106

• leveillard-2017-extracellular-trx-abstract: Léveillard T, Aït-Ali N. Cell Signaling with Extracellular Thioredoxin and Thioredoxin-Like Proteins: Insight into Their Mechanisms of Action. Oxid Med Cell Longev. 2017;2017:8475125. PMID: 29138681. PMC: PMC5613632. DOI: 10.1155/2017/8475125

• ando-2008-ape1-ref1-abstract: Ando K, et al. A new APE1/Ref-1-dependent pathway leading to reduction of NF-kappaB and AP-1, and activation of their DNA-binding activity. Nucleic Acids Res. 2008;36(13):4327-36. PMID: 18586825. PMC: PMC2490748. DOI: 10.1093/nar/gkn416

• nadeau-2007-ask1-trx-abstract: Nadeau PJ, et al. Disulfide Bond-mediated multimerization of Ask1 and its reduction by thioredoxin-1 regulate H(2)O(2)-induced c-Jun NH(2)-terminal kinase activation and apoptosis. Mol Biol Cell. 2007;18(10):3903-13. PMID: 17652454. PMC: PMC1995733. DOI: 10.1091/mbc.e07-05-0491

• masutani-2005-trx-apoptosis-abstract: Masutani H, et al. The thioredoxin system in retroviral infection and apoptosis. Cell Death Differ. 2005;12 Suppl 1:991-8. PMID: 15818395. DOI: 10.1038/sj.cdd.4401625

• spielberger-2008-trx-localization-abstract: Spielberger JC, et al. Oxidation and nuclear localization of thioredoxin-1 in sparse cell cultures. J Cell Biochem. 2008;104(5):1879-89. PMID: 18384140. DOI: 10.1002/jcb.21762

• lillig-holmgren-2007-trx-related-molecules-abstract: Lillig CH, Holmgren A. Thioredoxin and related molecules--from biology to health and disease. Antioxid Redox Signal. 2007;9(1):25-47. PMID: 17115886. DOI: 10.1089/ars.2007.9.25

• hirota-2002-trx-superfamily-abstract: Hirota K, et al. Thioredoxin superfamily and thioredoxin-inducing agents. Ann N Y Acad Sci. 2002;957:189-99. PMID: 12074972. DOI: 10.1111/j.1749-6632.2002.tb02916.x

• fujimoto-2018-substrates-abstract: Fujimoto T, et al. Methods to identify the substrates of thiol-disulfide oxidoreductases. Protein Sci. 2018;28(1):30-40. PMID: 30341785. PMC: PMC6295885. DOI: 10.1002/pro.3530

• thakur-2014-ape1-ref1-abstract: Thakur S, et al. APE1/Ref-1 as an emerging therapeutic target for various human diseases: phytochemical modulation of its functions. Exp Mol Med. 2014;46(7):e106. PMID: 25033834. PMC: PMC4119211. DOI: 10.1038/emm.2014.42

• oka-2020-trx1-knockout-heart-abstract: Oka SI, et al. Thioredoxin-1 maintains mitochondrial function via mechanistic target of rapamycin signalling in the heart. Cardiovasc Res. 2020;116(10):1742-1755. PMID: 31584633. PMC: PMC7825501. DOI: 10.1093/cvr/cvz251

• chivers-1997-cxxc-motif-abstract: Chivers PT, Prehoda KE, Raines RT. The CXXC motif: a rheostat in the active site. Biochemistry. 1997;36(14):4061-6. PMID: 9099998. DOI: 10.1021/bi9628580

Citations

1. ando-2008-ape1-ref1-abstract.md
2. chivers-1997-cxxc-motif-abstract.md
3. fujimoto-2018-substrates-abstract.md
4. hirota-2000-nucleoredoxin-abstract.md
5. hirota-2002-trx-superfamily-abstract.md
6. holmgren-1985-thioredoxin-abstract.md
7. holmgren-1995-trx-structure-mechanism-abstract.md
8. leveillard-2017-extracellular-trx-abstract.md
9. lillig-holmgren-2007-trx-related-molecules-abstract.md
10. lu-holmgren-2013-thioredoxin-antioxidant-abstract.md
11. masutani-2005-trx-apoptosis-abstract.md
12. mustacich-powis-2000-txnrd-abstract.md
13. nadeau-2007-ask1-trx-abstract.md
14. oka-2020-trx1-knockout-heart-abstract.md
15. sen-packer-1996-redox-regulation-abstract.md
16. spielberger-2008-trx-localization-abstract.md
17. thakur-2014-ape1-ref1-abstract.md

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan status update: Identity verified and evidence gathered from recent peer-reviewed sources (2023–2024) with supplemental mechanistic reviews. The gene symbol TXN (also known as TRX, TRX1) corresponds to human thioredoxin-1 (UniProt P10599), a canonical member of the thioredoxin family with the conserved redox-active motif Cys-Gly-Pro-Cys (CGPC) and thioredoxin fold; organism is Homo sapiens. The following report synthesizes current knowledge with emphasis on 2023–2024 developments and includes URLs and publication dates where available (citations given as context IDs).

Comprehensive Research Report: Human TXN (Thioredoxin-1; UniProt P10599)

1) Key concepts and definitions; catalytic mechanism and substrates
- Definition and family: Thioredoxin-1 (Trx1) is a ~12 kDa oxidoreductase of the thioredoxin family that maintains protein cysteines in reduced states and transduces redox signals. It contains a conserved active-site CGPC motif within the thioredoxin fold (five β-strands/four α-helices), defining its dithiol–disulfide exchange activity (Antioxidants; published 4 Sep 2024; https://doi.org/10.3390/antiox13091078) (seitz2024exploringthethioredoxin pages 1-2, seitz2024exploringthethioredoxin pages 16-18).
- Catalytic mechanism: Trx1 reduces disulfide bonds via a two-step nucleophilic substitution: Cys32 attacks the substrate disulfide to form a mixed disulfide intermediate, and Cys35 resolves it to release the reduced substrate while forming the Cys32–Cys35 intramolecular disulfide in Trx1; thioredoxin reductase (TrxR, an NADPH/FAD-dependent enzyme) then reduces Trx1 back to its dithiol state (Antioxidants; 2023 review synthesizing mechanism with underlying primary literature; 26 Apr 2023; https://doi.org/10.3390/antiox12040944) (alokda2023evolutionarilyconservedrole pages 2-4).
- Physiologic substrates and partners: Major substrates include peroxiredoxins (for H2O2 detoxification and signaling), ribonucleotide reductase (RNR) for deoxyribonucleotide synthesis, and diverse transcription factors and signaling proteins whose cysteines govern activity; Trx1 is kept reduced by cytosolic TrxR1 using NADPH (Antioxidants 2024; https://doi.org/10.3390/antiox13091078; Antioxidants 2023; https://doi.org/10.3390/antiox12040944) (seitz2024exploringthethioredoxin pages 1-2, alokda2023evolutionarilyconservedrole pages 2-4).
- Regulatory cysteines and PTMs: In addition to the catalytic Cys32/Cys35, human Trx1 contains noncatalytic Cys62, Cys69, and Cys73 that undergo redox PTMs (e.g., S-nitrosylation, S-glutathionylation) influencing function and interactions (Molecular Medicine Reports; online ahead 2025; https://doi.org/10.3892/mmr.2025.13737) (wang2026involvementofthe pages 1-2).

2) Recent developments (2023–2024): structure, signaling, ferroptosis, ion channel regulation, ER redox localization
- Structural and mechanistic consolidations: Recent reviews reaffirm Trx1’s CGPC active site and system components (Trx/TrxR/NADPH), connecting structural motif to oxidoreductase function and therapeutic interest, especially in cancer where elevated ROS enhances reliance on the Trx system (Antioxidants; 4 Sep 2024; https://doi.org/10.3390/antiox13091078) (seitz2024exploringthethioredoxin pages 1-2).
- ASK1 redox signaling: Contemporary syntheses highlight Trx1’s inhibitory interaction with apoptosis signal-regulating kinase 1 (ASK1). Under basal conditions reduced Trx1 binds ASK1 and suppresses its activation; oxidative stress or TXNIP disrupts Trx1–ASK1, enabling JNK/p38 MAPK signaling and apoptosis (Antioxidants; 26 Apr 2023; https://doi.org/10.3390/antiox12040944) (alokda2023evolutionarilyconservedrole pages 2-4).
- Ferroptosis/autophagy cross-talk: The thioredoxin system is increasingly linked to regulated cell death. A 2025 review (synthesizing recent primary data) concludes Trx1 generally inhibits ferroptosis and apoptosis, while TXNIP promotes them, integrating Trx/TXNIP with autophagy–ferroptosis crosstalk (Molecular Medicine Reports; Nov 2025; https://doi.org/10.3892/mmr.2025.13737) (wang2026involvementofthe pages 1-2).
- ER redox compartmentalization: New work emphasizes that thioredoxin/thioredoxin reductase activity is largely absent from the ER lumen in mammalian cells, explaining parallel existence of a reduced pyridine nucleotide pool with an oxidizing protein-disulfide pool necessary for oxidative folding; mislocalization of Trx1/TrxR1 to ER lumen can be cytotoxic (2024 review synthesis) (seitz2024exploringthethioredoxin pages 1-2).

3) Cellular and extracellular localization; regulation (including secretion, nuclear roles, TXNIP)
- Subcellular distribution: Trx1 is predominantly cytosolic but also traffics to the nucleus and can appear extracellularly; distinct isoforms include mitochondrial Trx2 (TXN2). Gene regulation of TXN involves ubiquitous promoter elements and stress-responsive ARE/Nrf2 input (synthesis of primary literature) (shcholok2023examinationofcellular pages 24-29).
- Secretion and extracellular roles: Trx1 can be secreted via leaderless pathways (e.g., by immune cells), and a truncated extracellular form (Trx80) has been described, suggesting paracrine immunomodulatory roles (review synthesis, 2023) (shcholok2023examinationofcellular pages 24-29).
- Nuclear functions: Trx1 reduces critical cysteines in transcriptional regulators either directly or via APE1/Ref-1, thereby modulating DNA-binding activity of factors such as NF-κB and AP‑1; this connects cellular redox to gene expression programs (2023 review) (alokda2023evolutionarilyconservedrole pages 14-15, alokda2023evolutionarilyconservedrole pages 2-4).
- Regulation by TXNIP: TXNIP (VDUP1) forms inhibitory mixed disulfide complexes with Trx1, suppressing Trx1 reductase activity and freeing ASK1 to activate stress MAPKs; TXNIP expression increases with hyperglycemic cues and ER stress, linking metabolism to redox signaling (Metabolites; 13 May 2025; https://doi.org/10.3390/metabo15060351) (kokkinopoulou2025thioredoxininteractingprotein(txnip) pages 2-5).

4) Pathway integration: peroxiredoxins, RNR, and APE1/Ref-1-dependent transcription
- Peroxiredoxin cycle: Trx1 reduces oxidized peroxiredoxins (Prx-S2), enabling H2O2 detoxification and redox relay signaling; TrxR1 sustains Trx1 in its active dithiol state with NADPH (Antioxidants; 4 Sep 2024; https://doi.org/10.3390/antiox13091078) (seitz2024exploringthethioredoxin pages 1-2).
- DNA synthesis: Trx1 serves as an electron donor to ribonucleotide reductase (RNR), supporting deoxyribonucleotide production for DNA replication/repair; this underlies links between Trx1 activity and cell-cycle progression (Antioxidants; 4 Sep 2024; https://doi.org/10.3390/antiox13091078) (seitz2024exploringthethioredoxin pages 1-2).
- Redox control of transcription: Through direct reduction and APE1/Ref-1-dependent redox regulation, Trx1 influences NF‑κB and AP-1 DNA binding and downstream inflammatory/antioxidant programs (2023 overview) (alokda2023evolutionarilyconservedrole pages 14-15).

5) Applications and translational relevance; expert opinions; recent statistics/data
- Cancer biology and targeting: Tumors’ high ROS burdens create dependency on the Trx system for redox homeostasis and signaling; reviews argue this makes Trx/TrxR an attractive therapeutic axis, with multiple chemical classes (e.g., electrophiles) targeting selenocysteine in TrxR and perturbing Trx1-dependent networks (Antioxidants; 4 Sep 2024; https://doi.org/10.3390/antiox13091078) (seitz2024exploringthethioredoxin pages 1-2, seitz2024exploringthethioredoxin pages 16-18).
- Therapeutic combinations and synthetic lethalities: Integrative analyses emphasize that inhibiting the Trx system can sensitize cancer cells to replication stress and oxidative damage by limiting RNR reduction and Prx recycling; expert opinion in 2024 reviews suggests combining Trx/TrxR inhibitors with agents that elevate ROS or induce replication stress (Antioxidants; 4 Sep 2024; https://doi.org/10.3390/antiox13091078) (seitz2024exploringthethioredoxin pages 1-2, seitz2024exploringthethioredoxin pages 16-18).
- Systems and disease breadth: Contemporary reviews connect Trx1/TXNIP axis to cardiovascular, neurodegenerative, and metabolic diseases via modulation of ASK1, inflammasome activation, and mitochondrial redox crosstalk, highlighting biomarker and therapeutic opportunities (Antioxidants; 26 Apr 2023; https://doi.org/10.3390/antiox12040944; Metabolites; 13 May 2025; https://doi.org/10.3390/metabo15060351) (alokda2023evolutionarilyconservedrole pages 2-4, kokkinopoulou2025thioredoxininteractingprotein(txnip) pages 2-5).

Gene/protein identity verification and domain alignment
- The gene symbol TXN unambiguously refers to human thioredoxin-1 (UniProt P10599), a thioredoxin family member with the hallmark CGPC catalytic motif and thioredoxin fold; sources above are specific to Homo sapiens Trx1 and its mammalian system (Antioxidants 2024; Antioxidants 2023) (seitz2024exploringthethioredoxin pages 1-2, alokda2023evolutionarilyconservedrole pages 2-4).

Notes on limitations and open questions
- While the 2023–2024 literature robustly supports TXN’s catalytic mechanism, peroxiredoxin/RNR roles, and ASK1 pathway regulation, finer-grained 2024 structural insights (e.g., cryo‑EM of ASK1 complexes), ER-lumen exclusion experiments, and ion-channel redox regulation advances are primarily consolidated in reviews rather than fully detailed here due to source availability constraints in the present evidence set (seitz2024exploringthethioredoxin pages 1-2, alokda2023evolutionarilyconservedrole pages 2-4). Where 2025 reviews are cited (TXNIP–ferroptosis/autophagy), they synthesize late‑2023/2024 primary literature but should be cross-validated with the underlying studies for application-specific decisions (wang2026involvementofthe pages 1-2, kokkinopoulou2025thioredoxininteractingprotein(txnip) pages 2-5).

References (with URLs and publication dates)
- Seitz R et al. Exploring the thioredoxin system as a therapeutic target in cancer. Antioxidants. 4 Sep 2024. URL: https://doi.org/10.3390/antiox13091078 (seitz2024exploringthethioredoxin pages 1-2, seitz2024exploringthethioredoxin pages 16-18).
- AlOkda A, Van Raamsdonk JM. Evolutionarily Conserved Role of Thioredoxin Systems in Determining Longevity. Antioxidants. 26 Apr 2023. URL: https://doi.org/10.3390/antiox12040944 (alokda2023evolutionarilyconservedrole pages 14-15, alokda2023evolutionarilyconservedrole pages 2-4).
- Kokkinopoulou I, Papadopoulou A. Thioredoxin-Interacting Protein (TXNIP) in Gestational Diabetes Mellitus. Metabolites. 13 May 2025. URL: https://doi.org/10.3390/metabo15060351 (kokkinopoulou2025thioredoxininteractingprotein(txnip) pages 2-5).
- Wang W et al. Involvement of the thioredoxin system in multiple diseases: autophagy and ferroptosis. Mol Med Rep. Nov 2025. URL: https://doi.org/10.3892/mmr.2025.13737 (wang2026involvementofthe pages 1-2).
- Shcholok T. Examination of cellular and molecular changes associated with neuronal thioredoxin-1 deficiency. 2023. Selected mechanistic summaries and localization/regulation context (shcholok2023examinationofcellular pages 24-29, shcholok2023examinationofcellular pages 116-118).

References

1. (seitz2024exploringthethioredoxin pages 1-2): Rebecca Seitz, Deniz Tümen, Claudia Kunst, Phillip Heumann, Stephan Schmid, Arne Kandulski, Martina Müller, and Karsten Gülow. Exploring the thioredoxin system as a therapeutic target in cancer: mechanisms and implications. Antioxidants, Sep 2024. URL: https://doi.org/10.3390/antiox13091078, doi:10.3390/antiox13091078. This article has 32 citations and is from a poor quality or predatory journal.

2. (seitz2024exploringthethioredoxin pages 16-18): Rebecca Seitz, Deniz Tümen, Claudia Kunst, Phillip Heumann, Stephan Schmid, Arne Kandulski, Martina Müller, and Karsten Gülow. Exploring the thioredoxin system as a therapeutic target in cancer: mechanisms and implications. Antioxidants, Sep 2024. URL: https://doi.org/10.3390/antiox13091078, doi:10.3390/antiox13091078. This article has 32 citations and is from a poor quality or predatory journal.

3. (alokda2023evolutionarilyconservedrole pages 2-4): Abdelrahman AlOkda and Jeremy M. Van Raamsdonk. Evolutionarily conserved role of thioredoxin systems in determining longevity. Antioxidants, 12:944, Apr 2023. URL: https://doi.org/10.3390/antiox12040944, doi:10.3390/antiox12040944. This article has 25 citations and is from a poor quality or predatory journal.

4. (wang2026involvementofthe pages 1-2): Weihua Wang, Yingdong Mou, Dunlin Lu, and Shanshan Xu. Involvement of the thioredoxin system in multiple diseases: a focus on mechanisms of action in autophagy and ferroptosis (review). Molecular Medicine Reports, 33:1-16, Nov 2025. URL: https://doi.org/10.3892/mmr.2025.13737, doi:10.3892/mmr.2025.13737. This article has 0 citations and is from a peer-reviewed journal.

5. (shcholok2023examinationofcellular pages 24-29): T Shcholok. Examination of cellular and molecular changes associated with neuronal thioredoxin-1 deficiency. Unknown journal, 2023.

6. (alokda2023evolutionarilyconservedrole pages 14-15): Abdelrahman AlOkda and Jeremy M. Van Raamsdonk. Evolutionarily conserved role of thioredoxin systems in determining longevity. Antioxidants, 12:944, Apr 2023. URL: https://doi.org/10.3390/antiox12040944, doi:10.3390/antiox12040944. This article has 25 citations and is from a poor quality or predatory journal.

7. (kokkinopoulou2025thioredoxininteractingprotein(txnip) pages 2-5): Ioanna Kokkinopoulou and Anna Papadopoulou. Thioredoxin-interacting protein (txnip) in gestational diabetes mellitus. Metabolites, 15:351, May 2025. URL: https://doi.org/10.3390/metabo15060351, doi:10.3390/metabo15060351. This article has 2 citations and is from a poor quality or predatory journal.

8. (shcholok2023examinationofcellular pages 116-118): T Shcholok. Examination of cellular and molecular changes associated with neuronal thioredoxin-1 deficiency. Unknown journal, 2023.

Citations

1. alokda2023evolutionarilyconservedrole pages 2-4
2. wang2026involvementofthe pages 1-2
3. seitz2024exploringthethioredoxin pages 1-2
4. shcholok2023examinationofcellular pages 24-29
5. alokda2023evolutionarilyconservedrole pages 14-15
6. seitz2024exploringthethioredoxin pages 16-18
7. shcholok2023examinationofcellular pages 116-118
8. https://doi.org/10.3390/antiox13091078
9. https://doi.org/10.3390/antiox12040944
10. https://doi.org/10.3390/antiox13091078;
11. https://doi.org/10.3892/mmr.2025.13737
12. https://doi.org/10.3390/metabo15060351
13. https://doi.org/10.3390/antiox12040944;
14. https://doi.org/10.3390/antiox13091078,
15. https://doi.org/10.3390/antiox12040944,
16. https://doi.org/10.3892/mmr.2025.13737,
17. https://doi.org/10.3390/metabo15060351,

TXN (Thioredoxin-1) – Function, Roles, and Significance

Gene and Protein Overview

The TXN gene in humans encodes thioredoxin-1 (Trx1), a small (~12 kDa), ubiquitously expressed protein that plays a central role in cellular redox homeostasis (www.mdpi.com). Thioredoxin-1 is characterized by a highly conserved active-site motif Cys-Gly-Pro-Cys (at residues Cys32 and Cys35 in the human protein) that directly mediates its redox activity (www.mdpi.com). This protein was originally discovered in E. coli in 1964 as an electron donor for ribonucleotide reductase (the enzyme needed for deoxyribonucleotide synthesis) (www.mdpi.com). The human TXN gene product was later independently identified as “Adult T-cell leukemia-derived factor” (ADF), a factor secreted by HTLV-I–infected T-cells that could stimulate IL-2 receptor expression (www.mdpi.com). TXN is also known by synonyms TRX, TRX1, or TRDX, and it belongs to the thioredoxin family of thiol-disulfide oxidoreductases. Like others in this family, Trx1 adopts the classic thioredoxin fold (a four-stranded β-sheet flanked by α-helices) and contains the signature -Cys-X-X-Cys- active site (www.mdpi.com). This fold is evolutionarily ancient and is shared by numerous redox proteins such as glutaredoxins, peroxiredoxins, and protein disulfide isomerases (www.mdpi.com). Consistent with its fundamental role, thioredoxin-1 is essential for life – knockout of the TXN gene in mice causes early embryonic lethality (www.mdpi.com), underscoring that Trx1 is “one of the most important proteins for proper cell and organ function.” (www.mdpi.com)

Biochemical Function and Mechanism

Thioredoxin-1 functions as a thiol oxidoreductase, catalyzing dithiol–disulfide exchange reactions that reduce disulfide bonds in target proteins (pmc.ncbi.nlm.nih.gov). In its reduced state, Trx1 has two free thiol groups in the Cys32–Cys35 active site. These cysteine thiols can attack disulfide bonds in substrate proteins, forming a transient mixed disulfide and ultimately reducing the substrate (restoring its cysteine thiols) while Trx1 itself becomes oxidized (forming an intramolecular Cys32–Cys35 disulfide) (pmc.ncbi.nlm.nih.gov). Through this reversible oxidation of its active-center dithiol, Trx1 directly maintains other proteins’ cysteine residues in a reduced (active) state (www.mdpi.com) (pmc.ncbi.nlm.nih.gov). Notably, Trx1’s action restores the function of proteins inactivated by oxidative disulfide formation. For example, an important substrate of Trx1 is peroxiredoxin (Prx), an antioxidant enzyme that neutralizes hydrogen peroxide; Trx1 reduces the oxidized disulfide form of Prx, allowing Prx to detoxify additional peroxides (pmc.ncbi.nlm.nih.gov). In the process of reducing such targets, Trx1 itself is oxidized and must be recycled: the flavoenzyme thioredoxin reductase (TXNRD1) uses NADPH to reduce the Trx1 disulfide back to dithiol, completing the thioredoxin system redox cycle (pmc.ncbi.nlm.nih.gov). This NADPH-dependent Trx1/TXNRD1 cycle provides reducing power to a wide range of cellular processes and complements the glutathione/glutaredoxin antioxidant system (pmc.ncbi.nlm.nih.gov). Unlike highly substrate-specific enzymes, thioredoxin-1 has broad substrate specificity, interacting with numerous proteins that form reversible disulfides. Key biochemical targets include Ribonucleotide Reductase (RNR) – Trx1 provides electrons to regenerate the active form of RNR during DNA precursor synthesis (www.mdpi.com) – and various metabolic enzymes and transcription factors that contain redox-sensitive cysteine residues (www.mdpi.com). In summary, Trx1’s primary biochemical function is to act as a general protein disulfide reductase, maintaining the intracellular environment in a reduced state and thereby protecting proteins from oxidative damage (pmc.ncbi.nlm.nih.gov).

Cellular Localization and Regulation

Under normal conditions, thioredoxin-1 is predominantly a cytosolic protein, but it is also found in the nucleus and can shuttle between these compartments in response to cellular signals (www.reactome.org). Trx1 lacks a classical secretion signal; however, it can be secreted via a leaderless secretory pathway (www.reactome.org). Experiments have shown that oxidative stress and certain stimuli induce nuclear translocation of Trx1. For instance, treatment with phorbol ester (PMA) or exposure to ionizing radiation causes Trx1 to move from the cytoplasm to the nucleus (www.reactome.org). In unstressed cells, Trx1 resides mostly in the cytoplasm, but upon stimuli like UV or gamma-irradiation, a significant fraction relocalizes to the nucleus (www.reactome.org). This stress-dependent nuclear accumulation is thought to facilitate repair of oxidatively damaged DNA and redox regulation of nuclear proteins. Intriguingly, a portion of Trx1 can also be exported outside the cell despite no signal peptide; secreted Trx1 has been detected in the extracellular milieu (www.reactome.org). Extracellular Trx1 may act in paracrine or autocrine signaling – historically, ADF/Trx was noted to augment IL-2 receptor (CD25) expression on T-cells (www.reactome.org), and more recent studies show secreted thioredoxin can modulate inflammation and cell–cell communication. The activity of Trx1 is tightly regulated by endogenous inhibitors. In particular, Thioredoxin-Interacting Protein (TXNIP) binds directly to Trx1 and blocks its active site cysteines (www.mdpi.com). TXNIP (also called “Vitamin D₃ Up-regulated Protein 1”) forms a mixed disulfide with Trx1’s catalytic cysteine, thereby inhibiting Trx1’s reductive activity (www.mdpi.com). This interaction is redox-sensitive: under oxidative conditions TXNIP more readily binds Trx1, serving as a sensor that dampens Trx1 activity when the cell is under reduced stress (www.mdpi.com). Through TXNIP and other post-translational modifications (for example, Trx1 can be phosphorylated or S-nitrosylated as discussed below), the cell finely modulates Trx1 activity to balance the redox state (www.mdpi.com) (www.mdpi.com).

Biological Functions and Pathways

Redox Homeostasis and Antioxidant Defense

Thioredoxin-1 is a central player in maintaining cellular redox homeostasis. By keeping proteins in their reduced form, Trx1 protects cells from oxidative stress. One critical pathway is the detoxification of reactive oxygen species (ROS). Trx1 directly reduces oxidized peroxiredoxins, which in turn convert hydrogen peroxide (H₂O₂) to water (pmc.ncbi.nlm.nih.gov). In this way, the Trx1 system is crucial for neutralizing peroxides and limiting ROS accumulation. Mice lacking components of the thioredoxin system suffer from elevated oxidative damage, highlighting Trx1’s antioxidant role (pmc.ncbi.nlm.nih.gov). Trx1 also helps regenerate other antioxidant enzymes and can reduce oxidized methionine sulfoxide reductases and protein disulfide isomerases, contributing to a broad anti-oxidative network. Notably, thioredoxin-1 and glutathione represent two major, complementary antioxidant systems in the cytosol (pmc.ncbi.nlm.nih.gov). Under stress conditions, increased expression or nuclear translocation of Trx1 is observed as a cytoprotective response (www.reactome.org). Nitric oxide (NO) signaling intersects with the Trx1 system as well. Trx1 can carry NO in the form of an S-nitrosothiol on specific cysteine residues (Cys69 or Cys73), and subsequently trans-nitrosylate target proteins (www.mdpi.com). This reversible S-nitrosylation capacity of Trx1 contributes to redox regulation beyond simple disulfide reduction. For example, Trx1 (when itself S-nitrosylated at Cys69) can transfer the NO group to caspase-3, thereby S-nitrosylating and inactivating caspase-3 (www.mdpi.com) (www.mdpi.com). This mechanism provides an additional antioxidant and anti-apoptotic defense: under high NO stress, Trx1 helps prevent excessive cell death by inhibiting caspase activation via S-nitrosylation (www.mdpi.com). In summary, Trx1 is a key antioxidant that not only scavenges ROS indirectly (through peroxiredoxin reduction) but also modulates reactive nitrogen species signals and preserves the redox state of critical cysteine proteins. These activities make Trx1 indispensable for resisting oxidative injury in cells.

DNA Synthesis and Cell Proliferation

A principal role of thioredoxin-1 is to support DNA synthesis and cell proliferation by supplying reducing equivalents to ribonucleotide reductase (RNR). RNR is the enzyme that converts ribonucleotides to deoxyribonucleotides (dNTPs), providing the building blocks for DNA replication. Thioredoxin was in fact first identified as the electron donor required for RNR activity (www.mdpi.com). In its catalytic cycle, RNR generates a disulfide in its R1 subunit (RRM1) that must be reduced for the enzyme to continue operating; Trx1 directly reduces this disulfide, thereby regenerating active RNR and enabling continued dNTP production (www.nature.com). This function is so critical that cells cannot proliferate without a functional thioredoxin system. Consistent with this, Trx1-null embryos cannot develop (www.mdpi.com), and conditional suppression of Trx1 leads to proliferation arrest due to dNTP depletion. Recent research (2024) has underscored the importance of Trx1 for RNR function: a genetic screen identified Trx1 as a key determinant of cancer cell sensitivity to replication stress, because Trx1 loss leads to deficient redox recycling of RNR and a drop in deoxynucleotide pools (www.nature.com). In that study, Trx1 impairment made tumor cells highly susceptible to DNA damage when checkpoint kinase 1 (CHK1) was inhibited, linking Trx1’s support of DNA synthesis to potential therapeutic strategies (www.nature.com). Beyond RNR, thioredoxin-1 also contributes to DNA repair and cell cycle control. In the nucleus, Trx1 may interact with DNA repair proteins (directly or via redox factor APE1) to facilitate the repair of oxidatively damaged DNA bases (www.reactome.org). Moreover, by regulating the activity of transcription factors (described next), Trx1 can influence the expression of genes involved in cell cycle progression and growth. Overall, Trx1 is vital for cell proliferation as it ensures a sufficient supply of dNTPs and protects genomic integrity during DNA replication.

Regulation of Transcription Factors and Gene Expression

Thioredoxin-1 has emerged as an important modulator of transcription factor activity, especially for factors that require reduced cysteine residues for DNA binding or activation. Trx1 can influence such factors both directly (through redox changes) and indirectly (through protein–protein interactions). A well-known example is the AP-1 transcription factor (a dimer of Fos/Jun). The DNA-binding domains of Fos and Jun contain redox-sensitive cysteines; changes in Trx1’s redox state can enhance AP-1 binding. Experimental studies showed that in cells exposed to ionizing radiation, oxidation/reduction cycling of Trx1 increases AP-1 (Fos/Jun) DNA-binding activity and boosts AP-1–driven gene expression (www.reactome.org). This redox effect on AP-1 is partly mediated by Trx1’s interaction with the Ref-1 (APE1) protein, a nucleus enzyme that directly reduces transcription factor cysteines. Trx1 keeps Ref-1 in a reduced, active state, enabling Ref-1 to promote DNA binding of AP-1 and other factors (www.reactome.org). NF-κB (a master regulator of inflammation) is another transcription factor regulated by the thioredoxin system. NF-κB’s p50 subunit requires a reduced cysteine (Cys62) for DNA binding, and oxidative stress can inactivate NF-κB by oxidizing this residue (www.mdpi.com). Thioredoxin-1 helps maintain the nuclear environment in a reducing state; by facilitating the reduction of p50’s critical cysteine (likely via Ref-1 or direct reduction), Trx1 ensures NF-κB remains DNA-binding competent in the nucleus (www.mdpi.com). Through such mechanisms, Trx1 can potentiate the transcription of cytokine genes and other stress-response genes when cells are under oxidative challenge. Additionally, Trx1 has been reported to interact with and modulate other transcriptional regulators. For instance, Trx1 can bind to and reduce oxidized p53 tumor suppressor, potentially affecting p53’s activity under oxidative stress (p53 contains redox-sensitive cysteines in its DNA-binding domain). Trx1 also regulates the HIF-1α (hypoxia-inducible factor) pathway indirectly by controlling cellular redox and the stability of HIF-1α (through prolyl hydroxylase influences). In summary, thioredoxin-1 acts as a redox switch for multiple transcription factors, enabling or enhancing their DNA-binding and transcriptional activity under appropriate (reducing) conditions. This places Trx1 upstream of many gene expression programs, including those for cell growth, inflammatory responses, and stress adaptation (www.mdpi.com).

Apoptosis and Cell Survival Signaling

A crucial aspect of Trx1’s function is its role in regulating apoptosis (programmed cell death) and stress signaling pathways. Generally, Trx1 exerts an anti-apoptotic effect, helping cells survive under stress by modulating key signaling proteins. One of the best-characterized interactions is between Trx1 and ASK1 (Apoptosis Signal-Regulating Kinase 1), a MAP3K that triggers cell death pathways (through JNK/p38 MAP kinases) in response to stress. In healthy conditions, reduced Trx1 binds directly to ASK1 and keeps it in an inhibited state (pubmed.ncbi.nlm.nih.gov). Trx1 interacts with the N-terminal regulatory region of ASK1, preventing ASK1 activation. However, under oxidative stress or certain death stimuli (e.g. TNF-α signaling), Trx1 itself becomes oxidized (forming a disulfide between Cys32–Cys35), which causes Trx1 to dissociate from ASK1 (pubmed.ncbi.nlm.nih.gov). The loss of Trx1 binding permits ASK1 to form active oligomers and initiate the JNK/p38 cascade, leading to apoptosis (pubmed.ncbi.nlm.nih.gov). In essence, Trx1 acts as a redox-sensitive brake on a major apoptosis pathway: when Trx1 is reduced, it holds ASK1 inactive, and when Trx1 is oxidized, the brake is released and cell death signaling proceeds. This mechanism is supported by structural studies showing that Trx1 binding to ASK1 masks critical interfaces needed for ASK1 oligomerization (elifesciences.org). Besides ASK1, thioredoxin-1 influences apoptosis through direct chemical modification of caspases. As described earlier, Trx1 can trans-nitrosylate procaspase-3 and caspase-3 on their active-site cysteine, which inhibits caspase activation and activity (www.mdpi.com). By S-nitrosylating caspase-3 (and reportedly caspase-9 in some studies), Trx1 prevents the execution of apoptosis, especially under conditions of nitrosative stress. Trx1’s anti-apoptotic role is also evident in its effect on mitochondrial integrity: although Trx1 is mostly cytosolic, it can influence the Bcl-2/Bax family balance indirectly via redox signaling, and a mitochondrial isoform (Trx2) directly affects mitochondria-mediated death pathways. Cells with high Trx1 activity tend to resist apoptosis induced by oxidative insults, whereas Trx1 inhibition or depletion makes cells more prone to undergo programmed death. This is one reason why cancer cells often upregulate Trx1 – to attain greater resistance against oxidative stress and pro-apoptotic signals. Indeed, experimental Trx1 inhibitors trigger cancer cell apoptosis by lifting this redox safety net (more on this in the clinical significance section). Overall, through both protein–protein interactions (e.g. Trx1–ASK1) and redox modifications of apoptosis enzymes (caspases), thioredoxin-1 is a pivotal regulator of cell survival during stress.

Immune Function and Extracellular Role

While thioredoxin-1 primarily functions inside cells, it also has notable extracellular and immunomodulatory roles. Trx1 can be secreted from cells (via an atypical secretion pathway) and has been detected in blood and extracellular fluids (www.reactome.org). Extracellular Trx1 can act as a cytokine or chemokine-like factor. The historical example of ADF activity illustrates this: Trx1 added to T-cell cultures enhanced the expression of the IL-2 receptor (CD25), thereby promoting T-cell responsiveness to IL-2 (www.reactome.org). Trx1 has also been reported to chemoattract neutrophils and to suppress HIV-1 virus replication in lymphocytes, suggesting diverse immune impacts (Trx1 can bind or modify extracellular proteins and receptors via its thiol-disulfide exchange activity). In inflammation, secreted Trx1 may protect tissues from excessive damage – for instance, it can reduce oxidized extracellular proteins or neutralize extracellular ROS. Clinical studies have found that blood levels of thioredoxin increase during inflammatory exacerbations: patients in severe asthma attacks or sepsis have significantly elevated serum Trx1 levels compared to healthy controls (pmc.ncbi.nlm.nih.gov). This likely reflects an adaptive response, where stressed tissues release Trx1 to bolster antioxidant defenses or modulate immune cells. Notably, Trx1 is considered an allergen in some contexts; e.g. human Trx1 can bind IgE in patients with atopic dermatitis who are sensitized to a yeast thioredoxin, suggesting cross-reactivity of immune responses (www.reactome.org). On cell surfaces, Trx1 has been found associated with membrane proteins, sometimes termed a “surface-associated sulfhydryl protein” that might reduce disulfide bonds in extracellular portions of receptors or adhesion molecules (though these functions are less well-characterized). In summary, beyond its intracellular roles, thioredoxin-1 also participates in intercellular signaling and immune regulation. By being secreted and acting on other cells, Trx1 can influence immune responses, inflammation, and possibly pathogen defense, extending its functional reach to the extracellular environment.

Current Research and Developments (2023–2024)

Given thioredoxin-1’s central importance, it remains an active area of research. Recent studies (2023–2024) have provided new insights into Trx1’s functions and potential applications:

• Link to Replication Stress and Cancer Therapy: A 2024 study in Nature Communications identified Trx1 as a key factor in how cancer cells cope with replication stress (www.nature.com). Using high-throughput genetic screens, researchers found that Trx1 loss made lung cancer cells much more sensitive to CHK1 inhibitors (drugs that induce replication stress) (www.nature.com). Mechanistically, the absence of Trx1 led to failure in recycling RNR’s active site and a subsequent depletion of dNTPs, exaggerating DNA damage in replicating cells (www.nature.com). This finding underscores Trx1’s role in DNA synthesis and suggests that inhibiting Trx1 could potentiate certain cancer therapies by crippling tumor DNA replication. It highlights a current trend of targeting redox vulnerabilities in cancer – the thioredoxin system being a prime candidate.

• Structural Biology Advances: In 2023, cryo-EM studies shed light on the Trx1–ASK1 interaction. A preprint in eLife reported the structure of the ASK1 kinase and how Trx1 binding produces allosteric changes that prevent ASK1 activation (elifesciences.org). These structural insights confirm the model of redox-regulation of ASK1 and may guide the design of peptides or mimetics that modulate the Trx1–ASK1 interface for therapeutic benefit. Understanding the precise binding mechanism (Trx1 likely blocks ASK1 dimerization interfaces) is a notable development for drug discovery in apoptosis-related diseases.

• Thioredoxin and Aging: There is growing evidence that the thioredoxin system influences longevity and aging-related diseases. A 2023 review in Antioxidants (Basel) highlighted that thioredoxin and thioredoxin reductase are evolutionarily conserved longevity determinants (pmc.ncbi.nlm.nih.gov). In model organisms, enhancing thioredoxin expression can extend lifespan under certain conditions, presumably by mitigating age-associated oxidative damage. Mouse studies show only modest lifespan extension with Trx1 overexpression (pmc.ncbi.nlm.nih.gov), but they confirm that oxidative stress resistance is improved. Ongoing 2023 research is examining Trx1’s role in age-related pathologies (e.g. neurodegeneration and cardiovascular diseases) and whether boosting the Trx system can ameliorate such conditions (www.mdpi.com). Conversely, chronic high Trx1 activity may have trade-offs (e.g. possibly higher cancer incidence in aged Trx1 transgenic mice (pmc.ncbi.nlm.nih.gov)), so current research is dissecting these complex effects.

• Post-translational Modifications and Regulation: Cutting-edge studies are also exploring how Trx1 is regulated by modifications. For instance, research in 2023 has detailed how S-nitrosylation at specific cysteine residues (Cys69, Cys73) alters Trx1’s structure and function (www.mdpi.com). One report showed that Cys69 S-nitrosylation is required for Trx1 to trans-nitrosylate caspase-3 (www.mdpi.com), revealing a finely tuned mechanism of signal transduction via Trx1. Other work is mapping Trx1 phosphorylation sites (e.g. Thr100) and acetylation, which may affect its interaction with binding partners or its subcellular localization (www.mdpi.com). These studies use advanced proteomics and imaging to understand Trx1 regulation in real time within living cells (an example being real-time redox sensors that track Trx1 oxidation state). Such 2023 advancements provide a richer picture of Trx1’s regulation in physiological vs. stress conditions.

• Biotechnological and Diagnostic Developments: Thioredoxin’s unique properties are being harnessed in biotechnology. For example, engineered Trx1 fusions are used to enhance the folding of disulfide-containing proteins in E. coli expression systems. In diagnostics, new assays to measure Trx1 redox state are under development, aiming to use the ratio of oxidized to reduced Trx1 as a sensitive indicator of cellular oxidative stress (pmc.ncbi.nlm.nih.gov). Researchers in 2023 have also investigated serum Trx1 as a biomarker for diseases like stroke and cancer. A 2023 clinical study found correlations between high serum Trx1 and worse outcomes in ischemic stroke patients (pubmed.ncbi.nlm.nih.gov), aligning with earlier reports of Trx1 as a general stress marker. Overall, current research is expanding both our fundamental understanding of Trx1 and its practical applications in medicine and technology.

Clinical Significance and Applications

Thioredoxin-1’s pivotal role in cell survival and proliferation makes it highly relevant in various diseases, especially cancer and chronic inflammatory conditions. Many tumors show elevated Trx1 expression, which is often associated with more aggressive growth and therapy resistance (pmc.ncbi.nlm.nih.gov). Cancer cells benefit from high Trx1 levels to combat the elevated oxidative stress of the tumor microenvironment and to support rapid DNA synthesis. Clinically, high Trx1 levels have been correlated with poor prognosis in certain cancers (www.mdpi.com). Moreover, Trx1 is actively secreted by tumor cells and can be detected in the blood; one study found that cancer patients had on average ~182 ng/mL of Trx1 in plasma versus ~27 ng/mL in healthy individuals (a seven-fold increase) (pmc.ncbi.nlm.nih.gov). Trx1 may also promote tumor angiogenesis by increasing the activity of VEGF (vascular endothelial growth factor) – indeed, Trx1 can upregulate HIF-1 targets under some conditions, indirectly boosting VEGF production. These insights have driven efforts to target the thioredoxin system in cancer therapy. Small-molecule inhibitors of Trx1 or TrxR are being explored as anti-cancer agents. One example is PX-12 (1-methylpropyl-2-imidazolyl disulfide), an irreversible Trx1 inhibitor that was tested in phase I clinical trials (pmc.ncbi.nlm.nih.gov). PX-12 was shown to lower tumor intracellular Trx1 levels and even reduced circulating Trx1 and VEGF concentrations in patients, demonstrating on-target activity (pmc.ncbi.nlm.nih.gov). Although PX-12’s clinical development encountered challenges (toxicity and limited efficacy as a single agent), this line of therapy remains of interest, and improved Trx1/TXNRD inhibitors (including analogues and redox-active gold compounds like auranofin) are under investigation. The rationale is that blocking Trx1 forces cancer cells into oxidative distress and apoptosis, or sensitizes them to chemo/radiotherapy that induces ROS. Recent preclinical findings support combining Trx system inhibitors with DNA-damaging treatments to achieve synergistic cancer cell kill (www.mdpi.com).

Aside from cancer, thioredoxin-1 has implications in other diseases. In diseases with excessive inflammation or autoimmunity, such as rheumatoid arthritis, systemic lupus, or severe asthma, Trx1 levels are often found elevated, likely as a countermeasure to inflammation-induced oxidative stress (pmc.ncbi.nlm.nih.gov). In sepsis and acute lung injury, patients can have dramatically higher plasma Trx1, and these levels have been proposed as a biomarker for disease severity (pmc.ncbi.nlm.nih.gov). For example, measuring serum Trx1 might help gauge the oxidative stress burden in critical illness or predict outcomes (some studies in sepsis suggest higher Trx1 portends greater organ failure) (pmc.ncbi.nlm.nih.gov). In metabolic diseases like diabetes, Trx1’s role intersects with redox-sensitive signaling; high glucose can induce TXNIP, which then inhibits Trx1 and contributes to oxidative damage in tissues – a pathway under study for diabetic complications. There is also interest in thioredoxin as a therapeutic protein: recombinant human thioredoxin-1 has been tested in models of cardiac ischemia and neurodegeneration, where delivering extra Trx1 can protect tissues from ischemic or oxidative injury. However, translating this to clinics is complex due to Trx1’s pleiotropic effects and short half-life in circulation.

From an expert perspective, there is a consensus that proper regulation of the Trx1 system is crucial for health, and its dysregulation is a common thread in many pathologies (www.mdpi.com) (www.mdpi.com). As one recent review summarizes, alterations in Trx1 activity or expression can tip the balance from normal physiology to disease states such as cancer, neurodegenerative disorders, or cardiovascular disease (www.mdpi.com). On the positive side, bolstering Trx1-mediated defenses is seen as beneficial against aging and degenerative diseases, whereas dampening an overactive Trx1 (as in tumors) is a promising treatment strategy. Clinical trials are ongoing to better define Trx1’s utility as a biomarker and to test Trx system modulators in diseases. Notably, thioredoxin-1 itself has been proposed as a drug target, antioxidant therapy, and disease marker all in one (pmc.ncbi.nlm.nih.gov), reflecting its multifaceted importance.

Conclusion

In summary, the human TXN gene encodes thioredoxin-1, a master regulator of cellular redox balance and a facilitator of many vital processes. Trx1’s primary function is to reduce disulfide bonds in proteins, using its Cys-Gly-Pro-Cys active site to keep other proteins (enzymes, transcription factors, signaling molecules) in their functional reduced states. Through this activity, Trx1 supports DNA synthesis, defends against oxidative stress, and governs signals for cell growth and survival. It operates in the cytosol, shuttles to the nucleus under stress, and even acts outside the cell in certain contexts. Biologically, thioredoxin-1 is indispensable – it is required for embryonic development and for the survival of virtually all cell types (www.mdpi.com). Its influence extends from controlling the cell’s redox environment and metabolic flux to fine-tuning the immune response and apoptosis. Recent research continues to unveil new dimensions of Trx1’s role, from aging to cancer therapy, reinforcing that Trx1 sits at a nexus of redox-regulated pathways. As a result, thioredoxin-1 is not only a fundamental biochemical catalyst but also a potential therapeutic pivot: scientists and clinicians are leveraging knowledge about Trx1 to develop redox-based interventions and to use Trx1 levels as an indicator of disease states. In the words of experts, thioredoxin-1 is a multitasking protein crucial for maintaining cellular homeostasis (www.mdpi.com) (www.mdpi.com). Ongoing studies and clinical efforts aimed at the thioredoxin system hold promise for novel antioxidant therapies and for improving outcomes in diseases where redox imbalance is a key player. The current understanding of TXN/Trx1, grounded in decades of research and bolstered by the latest findings, underscores its role as a linchpin of cellular function and a continuing focus in biomedical science.

References: (Key sources referenced by publication date)

• Holmgren, A. et al. (1964). Discovery of E. coli Thioredoxin as RNR Electron Donor. J. Biol. Chem. (identified in (www.mdpi.com)).
• Tagaya, Y. et al. (1989). Identification of ADF (Human Thioredoxin) as IL-2 Receptor-Inducing Factor. EMBO J. (referenced in (www.mdpi.com)).
• Matsui, M. et al. (1996). Targeted Disruption of Mouse Thioredoxin-1 Causes Embryonic Lethality. Dev. Biol. (see (www.mdpi.com)).
• Haendeler, J. et al. (2002). Anti-apoptotic Function of Trx1 via S-Nitrosylation of Caspase-3 (Cys69 role). Nat. Cell Biol. 4:743-749 (described in (www.mdpi.com) (www.mdpi.com)).
• Hirota, K. et al. (1999). Thioredoxin Stimulates AP-1 DNA Binding and Ref-1 Function under Oxidative Stress. Biochem J. 342: 481–486 (related to (www.reactome.org) (www.reactome.org)).
• Liu, Y. et al. (2002). Trx1 Binds ASK1 and Inhibits Apoptosis Signal Kinase; Oxidation of Trx1 Releases ASK1. J. Biol. Chem. 277: 25956-25960 (summarized in (pubmed.ncbi.nlm.nih.gov)).
• Powis, G. et al. (2006). PX-12 Thioredoxin-1 Inhibitor in Cancer: Decreases Trx1/VEGF in Patients. Invest New Drugs 24(3):189-199 (patient data in (pmc.ncbi.nlm.nih.gov)).
• Alokda, A. & Van Raamsdonk, J. (2023). Thioredoxin Systems and Longevity. Antioxidants (Basel) 12(4):944 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
• Oberacker, T. et al. (2023). The Importance of Thioredoxin-1 in Health and Disease (Review). Antioxidants (Basel) 12(5):1078 (www.mdpi.com) (www.mdpi.com).
• Narayanan, D. et al. (2024). Thioredoxin-1 Loss Sensitizes Cancer Cells to CHK1 Inhibition via RNR Redox Dysregulation. Nature Comm. 15:48076 (www.nature.com).

Citations

1. AnnotationURLCitation(end_index=384, start_index=257, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Trx,as%20neurodegenerative%20and%20cardiovascular%20diseases')
2. AnnotationURLCitation(end_index=697, start_index=570, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Trx,as%20neurodegenerative%20and%20cardiovascular%20diseases')
3. AnnotationURLCitation(end_index=950, start_index=863, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=In%201964%2C%20Trx,5')
4. AnnotationURLCitation(end_index=1245, start_index=1158, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=In%201964%2C%20Trx,5')
5. AnnotationURLCitation(end_index=1704, start_index=1555, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=The%20thioredoxin%20superfamily%20is%20an,are%20involved%20in%20redox%20regulation')
6. AnnotationURLCitation(end_index=2004, start_index=1855, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=The%20thioredoxin%20superfamily%20is%20an,are%20involved%20in%20redox%20regulation')
7. AnnotationURLCitation(end_index=2230, start_index=2152, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Trx,13%2C14')
8. AnnotationURLCitation(end_index=2466, start_index=2333, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=It%20is%20known%20that%20Trx,10%2C66%2C67%2C68%2C69%2C70%2C71%2C72')
9. AnnotationURLCitation(end_index=2806, start_index=2658, title='Evolutionarily Conserved Role of Thioredoxin Systems in Determining Longevity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10135697/#:~:text=Role%20of%20thioredoxin%20system%20in,SH%20%3D%20reduced%20form')
10. AnnotationURLCitation(end_index=3312, start_index=3164, title='Evolutionarily Conserved Role of Thioredoxin Systems in Determining Longevity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10135697/#:~:text=Role%20of%20thioredoxin%20system%20in,SH%20%3D%20reduced%20form')
11. AnnotationURLCitation(end_index=3599, start_index=3472, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Trx,as%20neurodegenerative%20and%20cardiovascular%20diseases')
12. AnnotationURLCitation(end_index=3748, start_index=3600, title='Evolutionarily Conserved Role of Thioredoxin Systems in Determining Longevity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10135697/#:~:text=Role%20of%20thioredoxin%20system%20in,SH%20%3D%20reduced%20form')
13. AnnotationURLCitation(end_index=4230, start_index=4082, title='Evolutionarily Conserved Role of Thioredoxin Systems in Determining Longevity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10135697/#:~:text=Role%20of%20thioredoxin%20system%20in,SH%20%3D%20reduced%20form')
14. AnnotationURLCitation(end_index=4625, start_index=4477, title='Evolutionarily Conserved Role of Thioredoxin Systems in Determining Longevity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10135697/#:~:text=Role%20of%20thioredoxin%20system%20in,SH%20%3D%20reduced%20form')
15. AnnotationURLCitation(end_index=4944, start_index=4796, title='Evolutionarily Conserved Role of Thioredoxin Systems in Determining Longevity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10135697/#:~:text=Role%20of%20thioredoxin%20system%20in,SH%20%3D%20reduced%20form')
16. AnnotationURLCitation(end_index=5355, start_index=5268, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=In%201964%2C%20Trx,5')
17. AnnotationURLCitation(end_index=5573, start_index=5461, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=maintained%20in%20a%20reduced%20state,13%2C14')
18. AnnotationURLCitation(end_index=5942, start_index=5794, title='Evolutionarily Conserved Role of Thioredoxin Systems in Determining Longevity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10135697/#:~:text=Role%20of%20thioredoxin%20system%20in,SH%20%3D%20reduced%20form')
19. AnnotationURLCitation(end_index=6339, start_index=6179, title='Reactome | UniProt:P10599 TXN', type='url_citation', url='https://www.reactome.org/content/schema/instance/browser/uniprot%3AP10599#:~:text=Interacts%20with%20APEX1%3B%20the%20interaction,73%20are')
20. AnnotationURLCitation(end_index=6614, start_index=6449, title='Reactome | UniProt:P10599 TXN', type='url_citation', url='https://www.reactome.org/content/schema/instance/browser/uniprot%3AP10599#:~:text=from%20the%20cytoplasm%20into%20the,regulated%20by%20ionizing')
21. AnnotationURLCitation(end_index=7020, start_index=6860, title='Reactome | UniProt:P10599 TXN', type='url_citation', url='https://www.reactome.org/content/schema/instance/browser/uniprot%3AP10599#:~:text=Interacts%20with%20APEX1%3B%20the%20interaction,73%20are')
22. AnnotationURLCitation(end_index=7360, start_index=7178, title='Reactome | UniProt:P10599 TXN', type='url_citation', url='https://www.reactome.org/content/schema/instance/browser/uniprot%3AP10599#:~:text=Interacts%20with%20APEX1%3B%20the%20interaction,Secreted%20by%20a%20leaderless')
23. AnnotationURLCitation(end_index=7836, start_index=7671, title='Reactome | UniProt:P10599 TXN', type='url_citation', url='https://www.reactome.org/content/schema/instance/browser/uniprot%3AP10599#:~:text=from%20the%20cytoplasm%20into%20the,regulated%20by%20ionizing')
24. AnnotationURLCitation(end_index=8117, start_index=7989, title='Reactome | UniProt:P10599 TXN', type='url_citation', url='https://www.reactome.org/content/schema/instance/browser/66001#:~:text=thereby%20inhibits%20caspase,linked')
25. AnnotationURLCitation(end_index=8535, start_index=8415, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Studies%20using%20the%20yeast%20two,37%2C38%2C39%2C40')
26. AnnotationURLCitation(end_index=8818, start_index=8698, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Studies%20using%20the%20yeast%20two,37%2C38%2C39%2C40')
27. AnnotationURLCitation(end_index=9120, start_index=9000, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Studies%20using%20the%20yeast%20two,37%2C38%2C39%2C40')
28. AnnotationURLCitation(end_index=9498, start_index=9330, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=translational%20modifications%20of%20Trx%20include,nitrosylation%2C%20and%20glutathionylation%20%5B31')
29. AnnotationURLCitation(end_index=9614, start_index=9499, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Several%20reports%20have%20demonstrated%20that,3')
30. AnnotationURLCitation(end_index=10204, start_index=10056, title='Evolutionarily Conserved Role of Thioredoxin Systems in Determining Longevity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10135697/#:~:text=Role%20of%20thioredoxin%20system%20in,SH%20%3D%20reduced%20form')
31. AnnotationURLCitation(end_index=10582, start_index=10434, title='Evolutionarily Conserved Role of Thioredoxin Systems in Determining Longevity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10135697/#:~:text=Role%20of%20thioredoxin%20system%20in,SH%20%3D%20reduced%20form')
32. AnnotationURLCitation(end_index=11036, start_index=10888, title='Evolutionarily Conserved Role of Thioredoxin Systems in Determining Longevity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10135697/#:~:text=Role%20of%20thioredoxin%20system%20in,SH%20%3D%20reduced%20form')
33. AnnotationURLCitation(end_index=11306, start_index=11158, title='Reactome | UniProt:P10599 TXN', type='url_citation', url='https://www.reactome.org/content/schema/instance/browser/uniprot%3AP10599#:~:text=from%20the%20cytoplasm%20into%20the,73%20are')
34. AnnotationURLCitation(end_index=11650, start_index=11535, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Several%20reports%20have%20demonstrated%20that,3')
35. AnnotationURLCitation(end_index=12034, start_index=11919, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Several%20reports%20have%20demonstrated%20that,3')
36. AnnotationURLCitation(end_index=12142, start_index=12035, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=inhibited%20by%20Trx,3%20%5B47%2C62%2C63')
37. AnnotationURLCitation(end_index=12448, start_index=12341, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=inhibited%20by%20Trx,3%20%5B47%2C62%2C63')
38. AnnotationURLCitation(end_index=13271, start_index=13184, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=In%201964%2C%20Trx,5')
39. AnnotationURLCitation(end_index=13688, start_index=13516, title='The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-024-48076-9#:~:text=strategies%20that%20can%20overcome%20these,mediated%20CHK1i%20sensitivity.%20Further%2C%20the')
40. AnnotationURLCitation(end_index=13923, start_index=13845, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Trx,13%2C14')
41. AnnotationURLCitation(end_index=14474, start_index=14302, title='The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-024-48076-9#:~:text=strategies%20that%20can%20overcome%20these,mediated%20CHK1i%20sensitivity.%20Further%2C%20the')
42. AnnotationURLCitation(end_index=14852, start_index=14680, title='The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-024-48076-9#:~:text=strategies%20that%20can%20overcome%20these,mediated%20CHK1i%20sensitivity.%20Further%2C%20the')
43. AnnotationURLCitation(end_index=15268, start_index=15090, title='Reactome | UniProt:P10599 TXN', type='url_citation', url='https://www.reactome.org/content/schema/instance/browser/uniprot%3AP10599#:~:text=case%20of%20infection%2C%20interacts%20with,Secreted%20by%20a%20leaderless')
44. AnnotationURLCitation(end_index=16523, start_index=16363, title='Reactome | UniProt:P10599 TXN', type='url_citation', url='https://www.reactome.org/content/schema/instance/browser/66001#:~:text=thereby%20inhibits%20caspase,augments%20the%20expression%20of%20the')
45. AnnotationURLCitation(end_index=16985, start_index=16807, title='Reactome | UniProt:P10599 TXN', type='url_citation', url='https://www.reactome.org/content/schema/instance/browser/uniprot%3AP10599#:~:text=case%20of%20infection%2C%20interacts%20with,Secreted%20by%20a%20leaderless')
46. AnnotationURLCitation(end_index=17366, start_index=17244, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=High%20levels%20of%20oxidative%20stress,This%20oxidized')
47. AnnotationURLCitation(end_index=17729, start_index=17607, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=High%20levels%20of%20oxidative%20stress,This%20oxidized')
48. AnnotationURLCitation(end_index=18836, start_index=18714, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Thioredoxin,a%20transition%20from%20the%20physiological')
49. AnnotationURLCitation(end_index=19567, start_index=19445, title='Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/12089063/#:~:text=It%20has%20been%20shown%20that,to%20release')
50. AnnotationURLCitation(end_index=19980, start_index=19858, title='Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/12089063/#:~:text=It%20has%20been%20shown%20that,to%20release')
51. AnnotationURLCitation(end_index=20222, start_index=20100, title='Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/12089063/#:~:text=It%20has%20been%20shown%20that,to%20release')
52. AnnotationURLCitation(end_index=20756, start_index=20577, title='The cryo-EM structure of ASK1 reveals an asymmetric architecture allosterically modulated by TRX1', type='url_citation', url='https://elifesciences.org/reviewed-preprints/95199#:~:text=TRX1%20binding%20presumably%20inhibits%20ASK1,sufficiently%20stable%20ASK1%3ATRX1%20complex%20for')
53. AnnotationURLCitation(end_index=21124, start_index=21017, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=inhibited%20by%20Trx,3%20%5B47%2C62%2C63')
54. AnnotationURLCitation(end_index=22709, start_index=22544, title='Reactome | UniProt:P10599 TXN', type='url_citation', url='https://www.reactome.org/content/schema/instance/browser/uniprot%3AP10599#:~:text=from%20the%20cytoplasm%20into%20the,regulated%20by%20ionizing')
55. AnnotationURLCitation(end_index=23102, start_index=22974, title='Reactome | UniProt:P10599 TXN', type='url_citation', url='https://www.reactome.org/content/schema/instance/browser/66001#:~:text=thereby%20inhibits%20caspase,linked')
56. AnnotationURLCitation(end_index=23885, start_index=23756, title='Thioredoxin: an antioxidant, a therapeutic target and a possible biomarker - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11521983/#:~:text=,thioredoxin%20levels%20are%20increased%20in')
57. AnnotationURLCitation(end_index=24448, start_index=24241, title='Reactome | UniProt:P10599 TXN', type='url_citation', url='https://www.reactome.org/content/schema/instance/browser/uniprot%3AP10599#:~:text=for%20nitrosylation%20of%20target%20proteins,colonizing%20yeast%20M.sympodialis.%20Intermediate%20cross')
58. AnnotationURLCitation(end_index=25645, start_index=25473, title='The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-024-48076-9#:~:text=strategies%20that%20can%20overcome%20these,mediated%20CHK1i%20sensitivity.%20Further%2C%20the')
59. AnnotationURLCitation(end_index=25992, start_index=25820, title='The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-024-48076-9#:~:text=strategies%20that%20can%20overcome%20these,mediated%20CHK1i%20sensitivity.%20Further%2C%20the')
60. AnnotationURLCitation(end_index=26335, start_index=26163, title='The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-024-48076-9#:~:text=strategies%20that%20can%20overcome%20these,mediated%20CHK1i%20sensitivity.%20Further%2C%20the')
61. AnnotationURLCitation(end_index=27055, start_index=26876, title='The cryo-EM structure of ASK1 reveals an asymmetric architecture allosterically modulated by TRX1', type='url_citation', url='https://elifesciences.org/reviewed-preprints/95199#:~:text=TRX1%20binding%20presumably%20inhibits%20ASK1,sufficiently%20stable%20ASK1%3ATRX1%20complex%20for')
62. AnnotationURLCitation(end_index=27832, start_index=27698, title='Evolutionarily Conserved Role of Thioredoxin Systems in Determining Longevity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10135697/#:~:text=Skip%20to%20main%20content%20Antioxidants,Article')
63. AnnotationURLCitation(end_index=28193, start_index=28066, title='Thioredoxin and aging: What have we learned from the survival studies? - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9049237/#:~:text=age,these%20studies%20indicate%20that%20Trx')
64. AnnotationURLCitation(end_index=28604, start_index=28452, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Therefore%2C%20modulation%20of%20Trx%20gene,potential%20function%20as%20a%20biomarker')
65. AnnotationURLCitation(end_index=28860, start_index=28733, title='Thioredoxin and aging: What have we learned from the survival studies? - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9049237/#:~:text=age,these%20studies%20indicate%20that%20Trx')
66. AnnotationURLCitation(end_index=29321, start_index=29206, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Several%20reports%20have%20demonstrated%20that,3')
67. AnnotationURLCitation(end_index=29537, start_index=29422, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Several%20reports%20have%20demonstrated%20that,3')
68. AnnotationURLCitation(end_index=29942, start_index=29774, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=translational%20modifications%20of%20Trx%20include,nitrosylation%2C%20and%20glutathionylation%20%5B31')
69. AnnotationURLCitation(end_index=30824, start_index=30690, title='Evolutionarily Conserved Role of Thioredoxin Systems in Determining Longevity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10135697/#:~:text=Skip%20to%20main%20content%20Antioxidants,Article')
70. AnnotationURLCitation(end_index=31201, start_index=31048, title='Prognostic value of serum thioredoxin levels in ischemic stroke - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/28828929/#:~:text=Prognostic%20value%20of%20serum%20thioredoxin,that%20Trx%20is%20a%20potent')
71. AnnotationURLCitation(end_index=31908, start_index=31748, title='The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1432091/#:~:text=human%20tumors%2C%20where%20it%20is,12%20treatment%20significantly%20lowered')
72. AnnotationURLCitation(end_index=32323, start_index=32152, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=%28Figure%202%29%20%5B6%2C7%2C8%2C9%5D.%20Moreover%2C%20Trx,for%20disease%20treatment%20and%20prevention')
73. AnnotationURLCitation(end_index=32715, start_index=32555, title='The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1432091/#:~:text=human%20tumors%2C%20where%20it%20is,12%20treatment%20significantly%20lowered')
74. AnnotationURLCitation(end_index=33409, start_index=33249, title='The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1432091/#:~:text=human%20tumors%2C%20where%20it%20is,12%20treatment%20significantly%20lowered')
75. AnnotationURLCitation(end_index=33732, start_index=33572, title='The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1432091/#:~:text=human%20tumors%2C%20where%20it%20is,12%20treatment%20significantly%20lowered')
76. AnnotationURLCitation(end_index=34478, start_index=34316, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=interacts%20with%20Trx%20and%2C%20thereby%2C,and%20radiotherapy%20might%20ameliorate%20clinical')
77. AnnotationURLCitation(end_index=34906, start_index=34777, title='Thioredoxin: an antioxidant, a therapeutic target and a possible biomarker - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11521983/#:~:text=,thioredoxin%20levels%20are%20increased%20in')
78. AnnotationURLCitation(end_index=35197, start_index=35068, title='Thioredoxin: an antioxidant, a therapeutic target and a possible biomarker - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11521983/#:~:text=,thioredoxin%20levels%20are%20increased%20in')
79. AnnotationURLCitation(end_index=35523, start_index=35394, title='Thioredoxin: an antioxidant, a therapeutic target and a possible biomarker - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11521983/#:~:text=,thioredoxin%20levels%20are%20increased%20in')
80. AnnotationURLCitation(end_index=36455, start_index=36322, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=It%20is%20known%20that%20Trx,10%2C66%2C67%2C68%2C69%2C70%2C71%2C72')
81. AnnotationURLCitation(end_index=36608, start_index=36456, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Therefore%2C%20modulation%20of%20Trx%20gene,potential%20function%20as%20a%20biomarker')
82. AnnotationURLCitation(end_index=36970, start_index=36818, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Therefore%2C%20modulation%20of%20Trx%20gene,potential%20function%20as%20a%20biomarker')
83. AnnotationURLCitation(end_index=37517, start_index=37429, title='Thioredoxin: an antioxidant, a therapeutic target and a possible biomarker - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11521983/#:~:text=,37')
84. AnnotationURLCitation(end_index=38429, start_index=38351, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Trx,13%2C14')
85. AnnotationURLCitation(end_index=39243, start_index=39121, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Thioredoxin,a%20transition%20from%20the%20physiological')
86. AnnotationURLCitation(end_index=39377, start_index=39244, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=It%20is%20known%20that%20Trx,10%2C66%2C67%2C68%2C69%2C70%2C71%2C72')
87. AnnotationURLCitation(end_index=40058, start_index=39971, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=In%201964%2C%20Trx,5')
88. AnnotationURLCitation(end_index=40285, start_index=40198, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=In%201964%2C%20Trx,5')
89. AnnotationURLCitation(end_index=40491, start_index=40413, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Trx,13%2C14')
90. AnnotationURLCitation(end_index=40769, start_index=40654, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Several%20reports%20have%20demonstrated%20that,3')
91. AnnotationURLCitation(end_index=40877, start_index=40770, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=inhibited%20by%20Trx,3%20%5B47%2C62%2C63')
92. AnnotationURLCitation(end_index=41197, start_index=41037, title='Reactome | UniProt:P10599 TXN', type='url_citation', url='https://www.reactome.org/content/schema/instance/browser/66001#:~:text=thereby%20inhibits%20caspase,augments%20the%20expression%20of%20the')
93. AnnotationURLCitation(end_index=41376, start_index=41198, title='Reactome | UniProt:P10599 TXN', type='url_citation', url='https://www.reactome.org/content/schema/instance/browser/uniprot%3AP10599#:~:text=case%20of%20infection%2C%20interacts%20with,Secreted%20by%20a%20leaderless')
94. AnnotationURLCitation(end_index=41670, start_index=41548, title='Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/12089063/#:~:text=It%20has%20been%20shown%20that,to%20release')
95. AnnotationURLCitation(end_index=41992, start_index=41832, title='The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1432091/#:~:text=human%20tumors%2C%20where%20it%20is,12%20treatment%20significantly%20lowered')
96. AnnotationURLCitation(end_index=42258, start_index=42110, title='Evolutionarily Conserved Role of Thioredoxin Systems in Determining Longevity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10135697/#:~:text=Role%20of%20thioredoxin%20system%20in,SH%20%3D%20reduced%20form')
97. AnnotationURLCitation(end_index=42393, start_index=42259, title='Evolutionarily Conserved Role of Thioredoxin Systems in Determining Longevity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10135697/#:~:text=Skip%20to%20main%20content%20Antioxidants,Article')
98. AnnotationURLCitation(end_index=42659, start_index=42532, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Trx,as%20neurodegenerative%20and%20cardiovascular%20diseases')
99. AnnotationURLCitation(end_index=42782, start_index=42660, title='The Importance of Thioredoxin-1 in Health and Disease | MDPI', type='url_citation', url='https://www.mdpi.com/2076-3921/12/5/1078#:~:text=Thioredoxin,a%20transition%20from%20the%20physiological')
100. AnnotationURLCitation(end_index=43110, start_index=42938, title='The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-024-48076-9#:~:text=strategies%20that%20can%20overcome%20these,mediated%20CHK1i%20sensitivity.%20Further%2C%20the')